PTC THERAPEUTICS, INC.

SOUTH PLAINFIELD, NJ How do I update this listing?

PTC Therapeutics is based out of South Plainfield. PTC Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of orally administered and proprietary small-molecule drugs for patients living with serious and life-threatening conditions, including genetic and neuromuscular disorders, cancer, and infectious diseases. Its approach includes post-transcriptional control, RNA biology, and gene expression modulation by small-molecules.Whalewisdom has at least 2 13D filings, and 114 Form 4 filings The firm last filed a Form D notice of exempt offering of securities on 2020-06-12. The notice included securities offered of Equity

Create Email Alert

Contact Info

ptc therapeutics, inc.
100 CORPORATE COURT
SOUTH PLAINFIELD NJ    07080-2449

Business Phone: 9082227000
SEC SIC CODE:
2834-PHARMACEUTICAL PREPARATIONS
Current 13D/G Holdings
Stock Sector Shares Held Market Value Rank Source Source Date
MRI INTERVENTIONS COM USD0.01 POST REV SPLIT (MRIC) 2,956,991 999999 13D 2020-01-29

Active Schedule 13D and 13G events

Sign in to see

Form 4 - Recent Insider Transactions

Loading...

Form D Filings

Form D is a form to be used to file a notice of an exempt offering of securities with the Securities and Exchange Commission. Form D contains basic information about the offering and the company.

Form D Filings
Filing Date Form Type Industry Group Securities Offered Total Offering Amount Total Amount Sold Total Remaining
2020-06-12 D BIOTECHNOLOGY Equity 41,905,000 41,905,000 0
2020-05-14 D BIOTECHNOLOGY Equity 140,949,151 140,949,151 0
2018-09-05 D BIOTECHNOLOGY Equity 150,000,000 150,000,000 0
2013-05-15 D BIOTECHNOLOGY Equity 4,500,000 4,500,000 0
2013-03-21 D BIOTECHNOLOGY Equity 59,999,448 59,999,448 0
2013-02-12 D BIOTECHNOLOGY Debt,Option, Warrant or Other Right to Acquire Another Security 16,100,100 2,000,100 14,100,000
2012-06-13 D BIOTECHNOLOGY Equity 40,000,000 22,950,840 17,049,160
2009-12-22 D BIOTECHNOLOGY Equity 50,300,000 25,150,064 25,149,936
2009-10-07 D BIOTECHNOLOGY Option, Warrant or Other Right to Acquire Another Security 1,000,000 0 1,000,000
Other Issuers in Filings
Name Address
No Other Issuers
Related Parties included in filings
Name Address Relationship
ADAM KOPPEL subscription required
    DIRECTOR
ALLAN S. JACOBSON subscription required
    DIRECTOR
AXEL BOLTE subscription required
    DIRECTOR
CARL GOLDFISCHER subscription required
    DIRECTOR
CHRISTINE UTTER subscription required
    EXECUTIVE OFFICER
CLAUDIA HIRAWAT subscription required
    EXECUTIVE OFFICER
DAVID P. SOUTHWELL subscription required
    DIRECTOR
DAWN SVORONOS subscription required
    DIRECTOR
DEEPA PAKIANATHAN subscription required
    DIRECTOR
EMILY HILL subscription required
    EXECUTIVE OFFICER
EMMA REEVE subscription required
    DIRECTOR
ERIC PAUWELS subscription required
    EXECUTIVE OFFICER
GEOFFREY MCDONOUGH subscription required
    DIRECTOR
GLENN D. STEELE, JR. subscription required
    DIRECTOR
JEROME B. ZELDIS subscription required
    DIRECTOR
LANGDON L. MILLER subscription required
    EXECUTIVE OFFICER
LANGON L. MILLER subscription required
    EXECUTIVE OFFICER
MARCIO SOUZA subscription required
    EXECUTIVE OFFICER
MARK E. BOULDING subscription required
    EXECUTIVE OFFICER
MATTHEW B. KLEIN subscription required
    EXECUTIVE OFFICER
MICHAEL KRANDA subscription required
    DIRECTOR
MICHAEL SCHMERTZLER subscription required
    DIRECTOR
NEIL ALMSTEAD subscription required
    EXECUTIVE OFFICER
PETER SVENNILSON subscription required
    DIRECTOR
RICHARD ALDRICH subscription required
    DIRECTOR
SOREN CARLSEN subscription required
    DIRECTOR
STEPHANIE S. OKEY subscription required
    DIRECTOR
STUART W. PELTZ subscription required
    EXECUTIVE OFFICER DIRECTOR
WILLIAM BAIRD, III subscription required
    EXECUTIVE OFFICER

Elevate your investments